FDG PET, PET/CT, and breast cancer imaging
FDG PET, PET/CT, and breast cancer imaging
复制标题
DOI：
10.1148/rg.27si075517
复制
发表时间：
2007-10-01
期刊：
影响因子：
5.5
通讯作者：
Mankoff, David A.
中科院分区：
文献类型：
--
作者：
Rosen, Eric L.;Eubank, William B.;Mankoff, David A.
目前，正电子发射断层扫描（PET）和PET/计算机断层扫描（CT）在乳腺癌患者中的临床作用是在常规成像结果不确定或效用有限的情况下提供额外信息。目前，氟脱氧葡萄糖（FDG）PET在乳腺癌检测或腋窝淋巴结评估中没有临床作用，但这些都是积极研究的领域。FDG PET是传统分期程序的补充，不应取代骨造影或诊断CT。FDG PET和PET/CT已被证明在乳腺癌的再分期、对治疗反应的评价以及在常规成像结果不确定时作为解决问题的方法中特别有用。在这些情况下，FDG PET经常显示影响治疗的局部或未被怀疑的远处疾病。PET已被证明是一种特殊的能力，在局部晚期乳腺癌患者和转移性疾病的化疗反应的评价。
Currently, the clinical role of positron emission tomography ( PET) and PET/computed tomography ( CT) in patients with breast cancer is to provide additional information in select scenarios in which results of conventional imaging are indeterminate or of limited utility. There is currently no clinical role for fluorodeoxyglucose ( FDG) PET in detection of breast cancer or evaluation of axillary lymph nodes, but these are areas of active research. FDG PET is complementary to conventional staging procedures and should not be a replacement for either bone scintigraphy or diagnostic CT. FDG PET and PET/CT have been shown to be particularly useful in the restaging of breast cancer, in evaluation of response to therapy, and as a problem-solving method when results of conventional imaging are equivocal. In these situations, FDG PET often demonstrates locoregional or unsuspected distant disease that affects management. PET has demonstrated a particular capability for evaluation of chemotherapy response in both patients with locally advanced breast carcinoma and those with metastatic disease.